Unaddressed adverse effects, such as fatigue, significantly reduce patient confidence in care plans and negatively impact quality of life for individuals with lymphoma and chronic lymphocytic leukemia ...

Epcoritamab demonstrated a median CR of 36 months and a median progression-free survival of 37 months in LBCL patients.

A combination therapy that adds a recently approved drug to the current standard of care for newly diagnosed acute myeloid ...

Johnson & Johnson said the first clinical data from its ongoing Phase 1b study of JNJ-4496, a chimeric antigen receptor T-cell therapy, shows encouraging potential in treating large B-cell lymphoma, ...

Women with breast cancer who were also carriers of the BRCA1 or BRCA2 mutation and received textured breast implants as part ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

KITE-363, a dual-targeting CAR T-cell therapy, shows a strong safety profile and high responses in patients who have highly ...

A promising new treatment to combat "undruggable" cancers has been green-lit for a human trial in 2025. It's hoped the novel ...

DelveInsight’s, “Diffuse Large B-Cell Lymphoma Pipeline Insight 2025” report provides comprehensive insights about 70+ ...

Researchers found that altering key enzymes involved in redox balance could disrupt the metabolism of Myc-driven lymphomas, ...

In these mice, Myc is expressed under the control of the immunoglobulin heavy chain enhancer, which mimics the situation found in human Burkitt's lymphoma ('Eμ-Myc mice').

Background: Primary central nervous system lymphoma (PCNSL) is characterized by a lack of specificity and poor prognosis. Further understanding of the tumor heterogeneity and molecular phenotype of ...